
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) – Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Greenwich LifeSciences in a research note issued to investors on Wednesday, November 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.46) per share for the year, down from their prior estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($1.46) EPS.
Separately, Weiss Ratings raised Greenwich LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Greenwich LifeSciences has a consensus rating of “Hold” and a consensus price target of $70.00.
Check Out Our Latest Research Report on Greenwich LifeSciences
Greenwich LifeSciences Price Performance
Shares of NASDAQ:GLSI opened at $19.79 on Friday. The stock’s 50-day moving average is $16.78 and its 200 day moving average is $20.82. The company has a market cap of $290.52 million, a PE ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10.
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06).
Institutional Investors Weigh In On Greenwich LifeSciences
A number of hedge funds have recently added to or reduced their stakes in the stock. Ancora Advisors LLC increased its holdings in Greenwich LifeSciences by 101.2% in the 3rd quarter. Ancora Advisors LLC now owns 21,610 shares of the company’s stock worth $390,000 after acquiring an additional 10,870 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Greenwich LifeSciences by 44.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock valued at $1,025,000 after buying an additional 17,464 shares in the last quarter. BlackRock Inc. bought a new position in Greenwich LifeSciences in the 2nd quarter worth $11,398,000. Deutsche Bank AG purchased a new stake in Greenwich LifeSciences in the 2nd quarter worth $126,000. Finally, Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the second quarter valued at about $1,124,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting Greenwich LifeSciences
Here are a few of the latest stories about GLSI:
- Positive Sentiment: HC Wainwright raised its price target to $70 from $69 and kept its Buy rating, signaling continued confidence despite the forecast reductions. Greenwich LifeSciences stock gets price target boost from HC Wainwright
- Neutral Sentiment: Noble Financial issued forecasts for losses of $1.49 per share in FY2026 and $2.14 in FY2027. These are new estimates rather than reported results or announced changes to its prior forecasts.
- Negative Sentiment: HC Wainwright lowered its EPS forecasts across late 2026 and 2027. Its FY2026 estimate moved to a loss of $1.46 per share from $1.29, while its FY2027 forecast fell to a loss of $1.46 from $1.17. The wider expected losses are the clearest near-term negative in the updates.
Greenwich LifeSciences Company Profile
Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.
See Also
- Five stocks we like better than Greenwich LifeSciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
